Publications by authors named "Kevin Shenk"

Claim this Profile
N
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events.
Shirin Arastu-Kapur, Janet L Anderl, Marianne Kraus, Francesco Parlati, Kevin D Shenk

Clin Cancer Res· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
Francesco Parlati, Susan J Lee, Monette Aujay, Erika Suzuki, Konstantin Levitsky, Kevin D Shenk

Blood· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).
Han-Jie Zhou, Monette A Aujay, Mark K Bennett, Maya Dajee, Susan D Demo, Kevin D Shenk

J Med Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Deborah J Kuhn, Qing Chen, Peter M Voorhees, John S Strader, Kevin D Shenk

Blood· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.
Susan D Demo, Christopher J Kirk, Monette A Aujay, Tonia J Buchholz, Maya Dajee, Kevin D Shenk

Cancer Res· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability.
Elfatih Elzein, Prabha Ibrahim, Dmitry O Koltun, Ken Rehder, Kevin D Shenk

Bioorg Med Chem Lett· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-affinity relationships of 5'-aromatic ethers and 5'-aromatic sulfides as partial A1 adenosine agonists, potential supraventricular anti-arrhythmic agents.
Christopher F Morrison, Elfatih Elzein, Bob Jiang, Prabha N Ibrahim, Timothy Marquart, Kevin D Shenk

Bioorg Med Chem Lett· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel inhibitors of fatty acid oxidation as potential metabolic modulators.
Elfatih Elzein, Kevin Shenk, Prabha Ibrahim, Tim Marquart, Suresh Kerwar

Bioorg Med Chem Lett· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New fatty acid oxidation inhibitors with increased potency lacking adverse metabolic and electrophysiological properties.
Dmitry O Koltun, Timothy A Marquart, Kevin D Shenk, Elfatih Elzein, Yuan Li

Bioorg Med Chem Lett· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis